Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756267 | 0.90 | POLB (0.72) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL6753939 | 0.89 | POLB (0.75) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL4619202 | 0.87 | POLB (0.62) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL8974221 | 0.84 | POLB (0.58) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL9746753 | 0.84 | POLB (0.58) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL230157 | 0.83 | POLB (0.84) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL4113303 | 0.82 | DDAH1 (0.65) | POLBDDAH1NPC1RAB9APKM | |
| SCHEMBL22643715 | 0.81 | DDAH1 (0.54) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL29749508 | 0.80 | DDAH1 (0.72) | POLBDDAH1NPC1RAB9APDE10A | |
| SCHEMBL612507 | 0.80 | DDAH1 (0.72) | POLBDDAH1NPC1RAB9APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | claimed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | claimed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| EP-2758416-B1 | NICKEL CONTAINING HYDROSILYLATION CATALYSTS AND COMPOSITIONS CONTAINING THE CATALYSTS | DOW CORNING (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2758413-B1 | IRIDIUM CONTAINING HYDROSILYLATION CATALYSTS AND COMPOSITIONS CONTAINING THE CATALYSTS | DOW CORNING (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9775840-B2 | Peripherally acting opioid compounds | ALKERMES, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20020067486-A1 | Solderability assessment | AMERICAN COMPETITIVENESS INSTITUTE | 2002-06-06 | — | — | US | disclosed |
| JP-2001329378-A | WATER SOLUBLE PREFLUX, PRINTED CIRCUIT BOARD AND SURFACE TREATING METHOD FOR METAL OF PRINTED CIRCUIT BOARD | TAMURA KAKEN CO LTD | 2001-11-27 | — | — | JP | disclosed |
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | disclosed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5348590-A | Surface treating agent for copper or copper alloys | HITACHI, LTD. (JP) | 1994-09-20 | — | — | US | disclosed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | POLB 3534/4885DDAH1 1929/4885NPC1 2606/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | POLB 1589/4885DDAH1 3339/4885NPC1 2024/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | POLB 646/4885DDAH1 2056/4885NPC1 4526/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | POLB 3534/4885DDAH1 1929/4885NPC1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.